Technical Analysis for IBRX - ImmunityBio, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
MACD Bullish Signal Line Cross | Bullish | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Pocket Pivot | Bullish Swing Setup | 1.95% | |
Wide Bands | Range Expansion | 1.95% | |
Gapped Up | Strength | 1.95% | |
MACD Bearish Signal Line Cross | Bearish | 6.52% | |
Wide Bands | Range Expansion | 6.52% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 2.95% | |
Wide Bands | Range Expansion | 2.95% | |
Overbought Stochastic | Strength | 2.95% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | about 17 hours ago |
Fell Below 10 DMA | about 17 hours ago |
Down 2 % | about 18 hours ago |
Down 1% | about 18 hours ago |
10 DMA Support | about 19 hours ago |
Get a Trading Sidekick!
- Earnings date: 03/11/2024
ImmunityBio, Inc. Description
NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized, activated NK cells-as well as their activity against a broad range of cancers-has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest's goal is to transform medicine by bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Immune System Immunotherapy Infectious Diseases Cancer Treatment Cancer Immunotherapy Genomics Virotherapy Natural Killer Cell Lymphocytes Pelareorep
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 6.93 |
52 Week Low | 1.25 |
Average Volume | 3,939,751 |
200-Day Moving Average | 3.07 |
50-Day Moving Average | 4.33 |
20-Day Moving Average | 4.85 |
10-Day Moving Average | 5.10 |
Average True Range | 0.44 |
RSI (14) | 57.26 |
ADX | 14.14 |
+DI | 19.64 |
-DI | 15.00 |
Chandelier Exit (Long, 3 ATRs) | 4.22 |
Chandelier Exit (Short, 3 ATRs) | 4.70 |
Upper Bollinger Bands | 5.70 |
Lower Bollinger Band | 4.00 |
Percent B (%b) | 0.72 |
BandWidth | 35.00 |
MACD Line | 0.23 |
MACD Signal Line | 0.23 |
MACD Histogram | 0.0009 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 5.76 | ||||
Resistance 3 (R3) | 5.75 | 5.56 | 5.67 | ||
Resistance 2 (R2) | 5.56 | 5.42 | 5.57 | 5.64 | |
Resistance 1 (R1) | 5.39 | 5.34 | 5.48 | 5.41 | 5.61 |
Pivot Point | 5.20 | 5.20 | 5.25 | 5.21 | 5.20 |
Support 1 (S1) | 5.04 | 5.07 | 5.12 | 5.05 | 4.85 |
Support 2 (S2) | 4.85 | 4.99 | 4.86 | 4.82 | |
Support 3 (S3) | 4.69 | 4.85 | 4.79 | ||
Support 4 (S4) | 4.70 |